Endothelium in embryonic hematopoietic tissues generates hematopoietic stem/progenitor cells; however, it is unknown how its unique potential is specified. We show that transcription factor Scl/ Tal1 is essential for both establishing the hematopoietic transcriptional program in hemogenic endothelium and preventing its misspecification to a cardiomyogenic fate. Scl À/À embryos activated a cardiac transcriptional program in yolk sac endothelium, leading to the emergence of CD31 + Pdgfra + cardiogenic precursors that generated spontaneously beating cardiomyocytes. Ectopic cardiogenesis was also observed in Scl À/À hearts, where the disorganized endocardium precociously differentiated into cardiomyocytes. Induction of mosaic deletion of Scl in Scl fl/fl Rosa26Cre-ER T2 embryos revealed a cell-intrinsic, temporal requirement for Scl to prevent cardiomyogenesis from endothelium. Scl À/À endothelium also upregulated the expression of Wnt antagonists, which promoted rapid cardiomyocyte differentiation of ectopic cardiogenic cells. These results reveal unexpected plasticity in embryonic endothelium such that loss of a single master regulator can induce ectopic cardiomyogenesis from endothelial cells.
SUMMARY
Endothelium in embryonic hematopoietic tissues generates hematopoietic stem/progenitor cells; however, it is unknown how its unique potential is specified. We show that transcription factor Scl/ Tal1 is essential for both establishing the hematopoietic transcriptional program in hemogenic endothelium and preventing its misspecification to a cardiomyogenic fate. Scl À/À embryos activated a cardiac transcriptional program in yolk sac endothelium, leading to the emergence of CD31 + Pdgfra + cardiogenic precursors that generated spontaneously beating cardiomyocytes. Ectopic cardiogenesis was also observed in Scl À/À hearts, where the disorganized endocardium precociously differentiated into cardiomyocytes. Induction of mosaic deletion of Scl in Scl fl/fl Rosa26Cre-ER T2 embryos revealed a cell-intrinsic, temporal requirement for Scl to prevent cardiomyogenesis from endothelium. Scl
INTRODUCTION
The hematopoietic and cardiovascular systems are the first organ systems to develop due to their essential functions in supporting the embryo. Blood cells, the heart, and the vasculature are generated from lateral plate mesoderm (Fehling et al., 2003; Kattman et al., 2006) in a highly coordinated process that ultimately facilitates the circulation of blood cells in the endothelium-lined blood vessels. The high mortality from blood and cardiovascular diseases warrants studies to define the mechanisms that facilitate the establishment and regeneration of these cell types. However, the road map for generating stem/progenitor cells for the different mesodermal lineages is lacking, limiting our ability to derive these cells for clinical use.
It has now been established that the embryonic endothelium not only is a conduit for blood, but also serves as a source of hematopoietic stem/progenitor cells (HS/PCs) (Bertrand et al., 2010; Boisset et al., 2010; Chen et al., 2009; Eilken et al., 2009; Kissa and Herbomel, 2010; Lancrin et al., 2009; Zovein et al., 2008) . This unique ''hemogenic endothelium'' is found during a defined developmental window in intra-and extraembryonic tissues that generate HS/PCs, including the para-aortic splanchnopleura/aorta-gonad-mesonephros (pSP/AGM) region, the yolk sac, and the placenta (Chen et al., 2009; Rhodes et al., 2008; Zovein et al., 2008) . However, the mechanisms that govern hemogenic competence in the endothelium are poorly understood.
Fate choice toward cardiovascular and hematopoietic lineages begins when gastrulating cells invaginate through the (B) Sorting strategy used to isolate endothelial cells from control and Scl À/À yolk sacs (YSs). Cells lacking hematopoietic markers CD41 (green boxes), CD45, and
Ter119 but expressing CD31 + (blue boxes) were subjected to gene expression analysis.
primitive streak; timing and localization of ingression dictates which morphogens nascent mesodermal cells encounter while migrating to their destination (Kinder et al., 2001) . Morphogens that regulate mesodermal fate choice include Wnt, Fgf, TGFb, and BMP (Nostro et al., 2008; Simõ es et al., 2011) . Combinations of these morphogens and their relative levels promote the patterning of the mesoderm to different cardiovascular and hematopoietic fates (Kattman et al., 2006 (Kattman et al., , 2011 Simõ es et al., 2011) . The bHLH transcription factor Scl/Tal1 is a candidate transcription factor responsible for specifying hemogenic endothelium from mesoderm (Lancrin et al., 2009) . Scl À/À embryos die by E 9.5 of mouse development due to absence of blood and poorly remodeled vasculature (Shivdasani et al., 1995; Visvader et al., 1998) . The requirement for Scl to specify the hematopoietic fate is limited to a narrow window; conditional deletion of Scl using the hematoendothelial-specific Tie2/Tek Cre strain or the interferon-inducible Mx Cre strain do not disrupt the generation or maintenance of HS/PC pool, although erythropoiesis and megakaryopoiesis are compromised (Mikkola et al., 2003b; Schlaeger et al., 2005) . Recent studies revealed that Scl becomes dispensable for HS/PC maintenance due to functional redundancy with a related bHLH factor Lyl1 (Souroullas et al., 2009) . Despite the critical role for Scl in the establishment of the hematopoietic system, little is known about how it generates HS/PCs. Chromatin immunoprecipitation (ChIP)-sequencing in embryonic HS/PCs and erythroid cells revealed widespread binding of Scl and other hematopoietic transcription across thousands of genes, many of which regulate hematopoietic stem cell (HSC) development or maintenance (Kassouf et al., 2010; Wilson et al., 2010) . However, these genome-wide binding studies have provided little information about the genes that depend on each of these factors for their expression.
Here we show that Scl establishes hemogenic endothelium by activating transcription factors required for HS/PC emergence and self-renewal. Moreover, our studies revealed an unexpected repressive role for Scl, as loss of Scl resulted in the generation of ectopic cardiomyocytes in yolk sac vasculature and the endocardium. These results uncover remarkable developmental plasticity in embryonic vasculature and identify Scl as a key determinant of endothelial fate choice.
RESULTS

Scl Establishes Hemogenic Competence in Endothelium
Embryos devoid of Scl lack embryonic red cells and HS/PCs in all hematopoietic tissues (Figures 1A and 1B; Figure S1A available online), providing an ideal in vivo model to study the establishment of the hematopoietic system. To determine which hematopoietic genes are activated in the endothelium in the yolk sac by Scl, we performed microarray analysis on Scl À/À and control CD31 + cells that were depleted of hematopoietic cells and compared them to CD41 + cKit + HS/PCs from control yolk sacs. Gene ontology enrichment analysis of the 1,295 differentially expressed genes (Table S1a) downregulated in Scl À/À endothelium (>1.5-fold, p < 0.05) revealed a robust Scl-dependent hematopoietic transcriptional program in yolk sac endothelium. These genes included transcription factors regulating HSC development (Runx1, cMyb, Fli1), Izkf1/ Ikaros, Erg, Gfi1) , and differentiation (Gata1 and Gfi1b), as well as surface proteins expressed on hematopoietic cells (Itga2b/ CD41, a marker of nascent HS/PCs (Bertrand et al., 2005; Mikkola et al., 2003a) and the panhematopoietic marker Ptprc/ CD45) ( Figure 1C ). Quantitative PCR (qPCR) on yolk sacs verified Scl dependence of key hematopoietic transcription factors (Figure 1D) . Immunofluorescence (IF) validated robust coexpression of CD41 in CD31 + endothelium of control but not Scl À/À yolk sacs ( Figure 1E ). These data indicate that Scl activates a network of hematopoietic transcription factors necessary for hemogenic competence in the endothelium.
Loss of Scl Provokes Ectopic Cardiogenesis in Hemogenic Tissues
To evaluate whether Scl has a repressive function in the endothelium in hemogenic tissues, GO enrichment analysis was performed for the 965 genes upregulated in CD31 + cells in Scl À/À yolk sacs. Unexpectedly, several highly significant GO categories were related to cardiogenesis and heart function (Figure 2A) . The upregulated genes included key cardiac transcription factors such as Isl1, Myocd, Smarcd3, and Tbx5, as well as several cardiomyocyte-specific structural proteins including Tnnt2, Myl7, Actc1, Myh6, Myh7, and Ryr2 ( Figure 2A ; Table  S1b ). qPCR analysis confirmed ectopic expression of cardiac genes in Scl À/À yolk sacs ( Figure 2B ), while fluorescenceactivated cell sorting (FACS) documented a population of cells expressing Troponin T (data not shown). IF revealed frequent coexpression of Troponin I (9.0 ± 4.5%) or T (19.5 ± 0.5%) in CD31 + cells in Scl À/À yolk sacs ( Figure 2C ), and whole mount staining identified clusters of ectopic cardiomyocytes scattered throughout the yolk sac ( Figure 2D ). Furthermore, explant cultures of Scl À/À yolk sacs produced colonies of synchronously beating cardiomyocytes (Movies S1A and S1B; Figure 2E Figure S1 and Tables S1A and S2A. were capable of storing Ca 2+ within the sarcoplasmic reticulum, which was susceptible to caffeine-induced release ( Figure 2F ). These results demonstrate that Scl is critical for suppressing cardiomyogenesis in the yolk sac.
Scl Activates Hematopoiesis and Represses Cardiogenesis in Placental Vasculature
To investigate if Scl also modulates endothelial fate in other hematopoietic tissues, we performed microarray analysis on CD31 + cells in the placenta, another site that can generate multipotent HS/PCs (Rhodes et al., 2008; Zeigler et al., 2006) . These results verified that also in placental endothelium, Scl activates many of the same hematovascular transcription factors as in the yolk sac, with the addition of Sox17 and Bmi1 that regulate self-renewal of fetal and adult HSCs (Kim et al., 2007; Park et al., 2003) (Table S2a) . No significant expression of cardiac structural proteins was detected in Scl À/À placental endothelium; however, there was expression of transcription factors essential for cardiac progenitor cell function including Isl1 and Smyd1, as well as cardiac morphogenesis genes including Has2, Dkk1, and Vcan (Figures S1B and S1C; Table  S2b ). These results indicate that the misspecification of prospective hemogenic endothelium to the cardiac fate is not limited to the yolk sac.
Loss of Scl Leads to the Emergence of CD31
+ Pdgfra + Cardiogenic Cells from Prospective Hemogenic Endothelium To identify the cardiogenic cells in the vasculature, we screened the microarray data for surface proteins upregulated in Scl À/À endothelium in both the yolk sac and the placenta. Pdgfra, a marker of cardiogenic mesoderm (Kattman et al., 2011) , was significantly upregulated in Scl À/À endothelium in both tissues ( Figure 2A ; Figure S1C ). FACS analysis of E 9.25 conceptuses identified a subpopulation of CD31 + cells coexpressing Pdgfra in all hematopoietic tissues in Scl À/À embryos ( Figure 3A) . By Figure 3C ). The head endothelium in Scl À/À embryos neither generated CD31 + Pdgfra + cells ( Figure 3A ) nor expressed cardiac transcription factors ( Figure 3C ). Figure 4A ). Injection of tamoxifen results in a peak of the active drug 12 hr later, which facilitates nuclear localization of Cre (Zovein et al., 2008) . Injection of tamoxifen at E 6.5 did not result in a significant difference in the hematopoietic compartment; however, CD31 and caffeine (10 mM) were added at the indicated times. In all panels, error bars represent SEM. See also Figure S1 , Tables S1B and S2B , and Movie S1. Figure 4D ). These data verify a cell-intrinsic requirement for Scl in repressing ectopic cardiogenesis.
To investigate whether the requirement for Scl to repress the cardiomyogenesis continues after mesodermal fates have diverged, we initiated injection at E 7.5 and the embryos were harvested at E 10.5. In spite of later deletion, many Rosa26-Cre-ER T2 Scl fl/fl yolk sacs still generated CD31 + Pdgfra + cells ( Figure 4E ) and expressed cardiac transcription factors and structural proteins ( Figure 4F ). CD31
+ Pdgfra + cells were also observed in 2/8 placentas (data not shown). However, when the deletion was induced a day later, at E 8.5, cardiac conversion was no longer observed despite comparable excision efficiency (Figures 4G and 4H ; data not shown). These data suggest that Scl is required for the repression of the cardiac fate in hemogenic tissues for a limited developmental window.
Scl Inhibits Cardiomyocyte Differentiation in the Endocardium
As the loss of Scl induced ectopic cardiogenesis from endothelium in hematopoietic tissues, we next examined Scl À/À hearts for evidence of endothelial misspecification. The heartbeat was initiated in Scl À/À hearts despite structural defects and pericardial effusion ( Figure 5A ; data not shown). Scl À/À outflow tracts and right ventricles were hypomorphic compared to the left ventricle, and the atrial and ventricular septa were poorly formed. Moreover, the heart chambers were filled with poorly organized endocardium ( Figures 5A and 5B) . IF for CD31 and Troponin T revealed that a substantial population (16.7 ± 3.8%) of endocardial cells coexpressed cardiomyocyte-specific proteins (Figure 5B ), demonstrating misspecification of Scl À/À endocardium to cardiomyocytic fate. Notably, CD31 + Pdgfra + cells were found in both Scl À/À and control hearts, although they emerged earlier (E 8.5 ) and were more frequent (E 9.25) in Scl À/À hearts ( Figure 5C ). (Figures 5D and 5E ; Table S4 ). In functional assays, both the endocardium and CD31 + Pdgfra + cells from Scl À/À hearts generated beating cardiomyocytes that expressed Troponin T and displayed organized sarcomeres (Movies S3A, S3B, and S3C; Figure 5F ). These data indicate that Scl suppresses cardiomyocyte differentiation of endocardium and CD31 + Pdgfra + cells in the heart.
The Requirement for Scl to Suppress Cardiomyocyte Fate Extends Perinatally in the Heart
We next assessed whether the timing when Scl is required to suppress cardiomyocyte differentiation in the heart correlates with that in hemogenic tissues ( Figure S3A ). When induction was initiated at E 6.5 and embryos harvested at E 9.5, the expression of cardiac structural proteins (e.g., Myl7) was significantly increased in both CD31 Figure S3D and Movie S4). These data indicate that the requirement for Scl to repress the cardiomyocyte fate continues perinatally in CD31 + Pdgfra + cells in the heart ( Figure S3E ).
CD31
+ Pdgfra + Putative Cushion Mesenchymal Cells Emerge from Ve-cadherin + Isl1 + Precursors during
Normal Development
As the requirement to repress cardiomyocyte differentiation in the later heart became confined to CD31 + Pdgfra + cells, we sought to define their identity and origin. CD31 + Pdgfra + cells in control hearts appeared first by E 9.25; their frequency peaked at around E 10.5 and then declined, although a small population persisted until early postnatal life ( Figure S4A ). IF demonstrated that CD31 + Pdgfra + cells in control hearts at E 9.5 were localized specifically to the outflow tract (OFT) and the atrioventricular canal (AVC) ( Figure S4B ), in contrast to Scl À/À hearts where CD31 + Pdgfra + cells were found throughout the heart (data not shown). Microarray analysis showed that the CD31 + Pdgfra + cells in normal hearts were enriched for cardiac transcription factors Smarcd3, Hand1, Gata4, and Gata6 ( Figure S4C ; Tables S4e  and S4f) See also Figure S2 , Table S3 , and Movie S2. Figure S4D ) (Alva et al., 2006; Stadtfeld and Graf, 2005) . In the heart, both CD31 + Pdgfra -endothelial cells as well as CD31 + Pdgfra + cushion mesenchymal cells evidenced equally efficient marking by the Ve-cadherin Cre ( Figure S4D ), although the latter had downregulated endothelial genes ( Figure S4E ). The efficiency of lineage tracing in placental and yolk sac endothelium and circulating HS/PCs was similar to that observed in the heart (data not shown Figures 6B and 6C ). Lack of ectopic cardiac differentiation in Runx1 À/À yolk sacs was further confirmed by qPCR (Figure 6E) . These results imply that, despite its pivotal role in the transition of hemogenic endothelium to HS/PCs, Runx1 is not required to repress cardiac conversion of endothelium ( Figure 6F ). As Isl1 À/À embryos showed a drastic reduction of CD31 + Pdgfra + cells in the heart ( Figure S4G ), we asked whether generation of cardiogenic CD31 + Pdgfra + cells in Scl À/À embryos was also dependent on Isl1 and generated Scl
Rosa26-YFP reporter strain (
Morphologically, Scl
phenotype with absence of blood, smaller embryonic size, and lack of pharyngeal arches and cardiac outflow tract ( Figure 6D ). It is interesting that CD31 + Pdgfra + cells were generated in the yolk sac and the heart of Scl
Isl1
À/À embryos, and cardiac transcription factors and structural proteins, including Gata6, Smarcd3, Myocd, Tnnt2, and Myl7, were ectopically expressed ( Figure 6E ). These data indicate that cardiac conversion in Scl À/À endothelium is independent of Isl1 ( Figure 6F ). (David et al., 2008; Jaspard et al., 2000; Schneider and Mercola, 2001) was also observed at E 8.5 ( Figure 7B Figure 7C ). Similar correlations were also observed in the heart and the placenta ( Figures S5A and S5B embryos were first injected with tamoxifen at E 6.5 to induce cardiogenic conversion and subsequently stimulated by the Wnt agonist LiCl, or control NaCl, after which yolk sacs were assayed for cardiomyocyte gene expression at E 11.5. qPCR revealed that the expression of cardiac structural proteins Myl7 and Tnnt2 was significantly reduced upon Wnt stimulation (Figure 7D) . Moreover, when Scl À/À yolk sacs were plated in explant culture and supplemented either with LiCl or NaCl throughout the 9 to 10-day culture, the colonies containing beating cardiomyocytes were larger and their size continued to increase over several days upon Wnt stimulation ( Figure 7E ). These results indicate that, in vivo, Scl À/À ectopic cardiogenic precursors experience Wnt antagonism that promotes cardiomyocyte differentiation; however, at least a subset of these cells retain the capacity to respond to Wnt stimulation ( Figure 7F ).
DISCUSSION
Our work has uncovered unexpected cardiogenic potential in prospective hemogenic endothelium in blood-forming tissues and endocardium in the heart. Upon loss of a single transcription factor, Scl, endothelium in these tissues gives rise to cardiogenic precursors that differentiate into spontaneously beating cardiomyocytes. The temporal window when Scl is required to repress cardiomyogenesis in hematopoietic tissues closely parallels the timing of HS/PC specification in hemogenic endothelium, while in the heart, the repressive function of Scl continues perinatally in CD31 + Pdgfra + putative cushion mesenchymal cells. Previous studies had suggested that Scl has mesoderm patterning activity during early development, as overexpression of Scl in mesoderm during embryonic stem cell differentiation promoted hematopoiesis at the expense of cardiac and paraxial mesoderm (Ismailoglu et al., 2008) . Likewise, modulation of Scl and Etsrp (zebrafish homolog for Etv2/ ER71) expression altered the size of the heart field (Schoenebeck et al., 2007) , and loss of Etsrp/Etv2 induced cardiomyocyte gene expression in endocardial progenitors (Palencia-Desai et al., 2011; Rasmussen et al., 2011) . These studies delineate a critical function for Scl and its upstream regulator Etsrp/Etv2 in promoting hematovascular fates over cardiac potential during mesoderm specification. Nevertheless, our finding that loss of Scl in the endothelium in hemogenic tissues and the heart after mesodermal tissues have diverged can give rise to fully functional, beating cardiomyocytes reveals unforeseen developmental plasticity in embryonic endothelium and identifies Scl as a master regulator of endothelial fate choice. Developmental fate decisions require precise orchestration of both cell-intrinsic and microenvironmental regulatory mechanisms. Modulation of Wnt signaling has pivotal effects at multiple stages of cardiac mesoderm and progenitor cell development: Wnt antagonists induce cardiac specification from mesoderm and promote cardiomyocyte differentiation (Schneider and Mercola, 2001; Ueno et al., 2007) , while activation of canonical Wnt signaling expands cardiac progenitors and maintains them in an undifferentiated state (Qyang et al., 2007) . Our study suggests that ectopic cardiomyogenic cells progress through a Wnt-responsive precursor state, the differentiation of which is promoted by Wnt antagonists. Nevertheless, our finding that cardiac conversion was cell intrinsic to loss of Scl, and could not be induced solely by secretion of Wnt inhibitors by neighboring Scl À/À cells, is in an agreement with the notion that morphogen-induced mesoderm patterning requires relatively uncommitted cells. Recent studies have documented conversion of other mesodermal tissues to cardiomyocytes in vitro and in vivo by reprogramming with a combination of cardiac transcription factors (Gata4, Tbx5, Smarcd3, and/ or Mef2c) (Ieda et al., 2010; Qian et al., 2012; Takeuchi and Bruneau, 2009) ; the same factors were also induced in Scl À/À yolk sac endothelial cells. Our data document that an altered cell-intrinsic regulatory program caused by loss Scl is sufficient to override the microenvironmental cues that dictate mesodermal fate.
Based on the localization of the CD31 + Pdgfra + in OFT and AVC in normal hearts, their gene expression (cardiac transcription factors and genes related to EMT) and endothelial origin, we proposed that these cells represent cushion mesenchymal cells, which give rise to the septa and valves (Yamagishi et al., 2009) 
FACS Analysis and Isolation of HS/PCs, Endothelial Cells, and Cardiac Cells
Cells from embryonic tissues were isolated as described elsewhere (Rhodes et al., 2008) . For details about FACS, see Extended Experimental Procedures.
Differential Gene Expression Analysis RNA was isolated using the RNeasy Micro kit (QIAGEN), amplified using the NuGEN Pico kit, and hybridized on Affymetrix Mouse Genome 430 2.0 Array GeneChip microarrays (GEO Accession Number GSE27445). For details on how differentially expressed genes were identified, analyzed and verified, see Extended Experimental Procedures.
Analysis of Tissue Sections and Whole Mounts by Confocal Microscopy
Fixed frozen sections were prepared and stained as described elsewhere (Rhodes et al., 2008) , with the same antibodies used in FACS, Troponin I (1:400, Santa Cruz) or cardiac Troponin T (1:400, Sigma). Whole mount yolk sacs were prepared as described elsewhere (Ahnfelt-Ronne et al., 2007) and stained for Troponin T. Confocal images were obtained on a Zeiss LSM 510 equipped with 405 nm, 488 nm, 543 nm, and 633 nm lasers. Images were processed with ImageJ software (National Institutes of Health [NIH] ).
Cardiac Culture Assays
Yolk sacs were mechanically dissociated by pipetting or enzymatically dissociated, sorted, and plated on OP9 stromal cells in cardiac medium (a-minimum essential medium with 20% fetal bovine serum, 5 ng/ml murine vascular endothelial growth factor, 50 ng/ml human bone morphogenetic protein 4, and 30 ng/ml human basic fibroblast growth factor; Peprotech) or directly on Matrigel and fibronectin-coated chamber slides (BD Biosciences) with or without 1 mM XAV939 (Wnt antagonist; Sigma), 2 mM LiCl (Wnt agonist), or 2 mM NaCl (control). Videos were taken with a Nikon Diaphot 300 microscope and XY Clone software (Hamilton Thorne Biosciences). Analysis of beating area was performed using VirtualDub software (v1.9.11) and ImageJ (NIH).
Measurement of Calcium Transients
Yolk sacs were cultured on petri dishes (MatTek Corporation) coated with Matrigel in cardiac medium for 9-10 days. Before imaging, explants were loaded with the Ca 2+ -sensitive dye Fluo-4AM (Molecular Probes) in the presence of . Spontaneous transients were imaged on a Zeiss LSM 5 Pascal confocal microscope equipped with a 488 nm laser.
In Vivo Manipulation of Regulation
Scl deletion in Rosa26Cre-ER T2 Scl fl/fl embryos was induced by Tamoxifen (Sigma Aldrich T5648) or (Z)-4-hydroxytamoxifen (Sigma Aldrich H7094).
Tamoxifen was suspended at 100 mg/ml in ethanol and mixed with sesame oil at a final concentration of 10 mg/ml (10% ethanol). Pregnant females were injected i.p. with 125 ml tamoxifen at the indicated days. Injections of 250 mg/kg NaCl and LiCl (Wnt agonist) were performed as described (Tian et al., 2010) .
Statistical Analysis
For statistical analysis, Student's unpaired two-tailed t test was used for all comparisons.
ACCESSION NUMBERS
For all array data, GEO Accession Number GSE27445 is given earlier, within the Experimental Procedures. 
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